Efficacy of Immunotherapy in Second-Line Treatment of <i>KRAS</i>-Mutated Patients with Non-Small-Cell Lung Cancer-Data from Daily Practice.

Curr Oncol · 2022 · PMC9858515 · PMID 36661686

Europe PMC DOI

hedged sentence

0.1850

closest p · 3.7× alpha

0.1850

boldest claim

The sentences

a statistical trendp = 0.185not close (p > 0.1)

In another study that evaluated immunotherapy in a group of 87 patients, those with the Gly12Asp variant had a higher probability of a therapeutic response (OR (95% CI) = 0.31 (0.09–0.95), p < 0.05) and a statistical trend toward improved survival (HR (95% CI) = 0.53 (0.21–1.36), p = 0.185) [ 22 ]. 4.3.

also in 2,798 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.